Vertex’s attempt to treat a rare genetic disease has hit another setback. The biotech tossed two more drug candidates onto the discard pile in response to underwhelming data but, following a playbook ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback